Business● Low3h ago · Nov 6, 2026, 2:45 AM
Castle Biosciences signals $385M-$395M 2026 revenue outlook as TissueCypher targets 50%-52% volume growth
GlobeAlert Desk · curated from Seeking Alpha Tech · North America
Castle Biosciences has provided a 2026 revenue outlook of $385 million to $395 million, driven by a targeted 50%-52% volume growth for its TissueCypher product. This indicates the company's financial projections and growth strategy.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Business
Not flagged as developing.
North America theater · last 7 days
rising · 27 in the last 24h1,027
events logged
97
risk index / 100
Attacks & Assaults 431Shootings 234Robberies & Theft 228Kidnappings 48Rocket Launches 37
- Cyber activity (116 reports)Cyber Threats · · 14m ago
- Protest activity (80 reports)Protests · · 15m ago
- Conflict activity (172 reports)Conflict Events · · 15m ago
More in Business
Business25m agoHong Kong’s Exchange Fund earnings tumble 74% as HKMA warns of more market turbulenceSouth China Morning PostBusiness25m agoCarlyle expects at least $20B of Q4 inflows as it targets about $60B for full-year 2026Seeking Alpha TechBusiness25m agoAnthropic's $1.5T valuation under pressure as major investors signal skepticism, WSJ reportsSeeking Alpha TechBusiness26m agoKLX Energy Services Non-GAAP EPS of -$0.44 misses by $0.09, revenue of $186M beats by $3.5MSeeking Alpha Tech